Long-term respiratory effects of e-cigarette use in adults are incompletely defined because widespread use is recent and high-quality longitudinal data are limited. Evidence to date indicates increased respiratory symptoms, altered lung function in some users, and plausible pathways for chronic injury, but causal links to diseases such as chronic obstructive pulmonary disease and lung cancer remain uncertain.
Evidence from population studies
A cross-sectional analysis by Arnab Bhatta and Stanton A. Glantz at University of California, San Francisco found that e-cigarette use was associated with self-reported respiratory disease after accounting for combustible cigarette smoking, suggesting a potential independent association with respiratory harm. The National Academies of Sciences, Engineering, and Medicine reviewed available literature and concluded there is substantial evidence that e-cigarette use increases cough and wheeze, and limited evidence for increased bronchitis symptoms. Public health surveillance reported by the Centers for Disease Control and Prevention emphasizes that many studies are cross-sectional or short-term, limiting ability to determine long-term outcomes.
Biological mechanisms and consequences
Laboratory and toxicology work by Maciej L. Goniewicz at Roswell Park Comprehensive Cancer Center and others demonstrates that e-cigarette aerosol contains nicotine, ultrafine particles, volatile organic compounds, and metals that can trigger airway inflammation, oxidative stress, and impaired mucociliary clearance. These biological effects provide plausible mechanisms by which recurring exposure could produce chronic changes in small airways and predispose to chronic bronchitic symptoms, more frequent respiratory infections, and worsened control or accelerated decline in people with asthma or COPD. Dual use of e-cigarettes and combustible cigarettes further increases exposure and likely magnifies risk.
Clinical and public health relevance includes increased symptom burden, greater healthcare utilization from exacerbations, and potential disparities where unregulated products are more common. Because lung cancer and many chronic airway diseases develop over decades, current evidence cannot firmly quantify long-term risks such as cancer incidence. Regulatory environments and cultural patterns of use shape exposure profiles; products with higher temperatures or illicit additives have produced outsized harms, illustrating territorial differences in risk.
In practice, clinicians should weigh these uncertainties against any individual benefit for smoking cessation, emphasize complete switching from combustible cigarettes rather than dual use, and monitor respiratory symptoms. Continued long-term cohort studies and standardized exposure assessments are essential to establish the magnitude and permanence of e-cigarette–related respiratory injury.